Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy consists of allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) developed by The First Affiliated Hospital of Air Force Medical University (also known as Xijing Hospital). It is currently being evaluated for the treatment of stage 3 or 4 chronic kidney disease (CKD) resulting from diabetic kidney disease or hypertensive nephropathy. The therapy utilizes the immunomodulatory, anti-inflammatory, and regenerative properties of mesenchymal stem cells to potentially slow disease progression and improve renal function, primarily assessed by changes in the estimated glomerular filtration rate (eGFR). The cells are administered via a single intravenous injection at a dose of 1.0×10^6 cells/kg.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord tissue-derived mesenchymal stem cells (Xijing Hospital).